spinal muscular atrophy
Revvity Nabs CE-IVD Mark for Molecular Newborn Screening Platform
The firm said its Eonis Q platform is used to identify spinal muscular atrophy and severe combined immunodeficiency with a turnaround time of about three hours.
State labs and commercial companies see rising spinal muscular atrophy test volumes as screening programs launch in US states and European countries, among others.
Fauna Bio Gets $373K NIH Grant to Study Animal Genomes for Potential Drug Targets
The company is studying hibernating animals to see if their genomes contain novel biological pathways that could be exploited to counteract complex human diseases.
Asuragen Receives CE Mark for Spinal Muscular Atrophy Assay
The test can help diagnose spinal muscular atrophy and identify carriers without symptoms who may be at risk of passing the disease to their children.
BillionToOne Closes $15M Series A Follow-on Round
The firm plans to use the cash to support commercial expansion of its NIPT to all US states and fund R&D for future diagnostic tests, including liquid biopsies.